Add-on therapy with dapagliflozin in routine outpatient care of type 2 diabetes patients from Turkey: a retrospective cohort study on HbA1c, body weight, and blood pressure outcomes

Ertuğrul, Derun Taner; Kan, Erdal; Tura, Çiğdem Bahadir; Tugtekin, Haci Bayram; Ayakta, Hayati; Çelebioğlu, Mehmet; Yılmaz, Ceren; Utebay, Onur; Yetkin, İlhan

doi:10.1007/s13410-021-00954-4

Cited by 3 publications

(1 citation statement)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the added benefit of SGLT2i in combination with other OHMs has been demonstrated in multiple randomized controlled trials (RCT), the comparative effectiveness of combination therapy with and without SGLT2i has not been established in a real-world setting. Several observational studies showed that adding or switching to SGLT2i significantly reduced HbA1c level from baseline [ 15 , 16 ]. However, to the best of our knowledge, no research has been done to evaluate if SGLT2i add-on therapy is more effective in glycemic control than treatments without SGLT2i in various combination regimens that are frequently prescribed in real-world clinical practice.…”

Section: Introductionmentioning

confidence: 99%

Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Added to Dual or Triple Treatment in Patients with Type 2 Diabetes Mellitus

Hong,

Jeon,

Choi

et al. 2023

Diabetes Ther

View full text Add to dashboard Cite

Introduction We evaluated the effectiveness and safety of sodium-glucose cotransporter 2 inhibitor (SGLT2i) add-on treatment in patients with type 2 diabetes mellitus (T2DM) in the real-world setting. Methods This single-center retrospective study used the clinical database of Seoul National University Hospital in South Korea. Patients who received metformin monotherapy or combination therapy with ≥ 1 other oral hypoglycemic medication and had a baseline glycosylated hemoglobin (HbA1c) between 7.0% and 10.5% were included. Propensity score matching was applied between patients treated with and without SGLT2 inhibitors (SGLT2i and non-SGLT2i groups, respectively). Changes in HbA1c from baseline to week 26 were compared between the SGLT2i and non-SGLT2i groups, and risk of adverse events (AE) were also assessed. Results A total of 1106 patients were included. At week 26, HbA1c was significantly more reduced by 0.35 percentage points in the SGLT2i group than in the non-SGLT2i group (95% CI 0.30–0.41, P < 0.001). Likewise, the proportion of patients achieving HbA1c < 7% was also significantly higher (51.9% vs. 37.6%, P < 0.05) in the SGLT2i group than in the non-SGLT2i group. The risk of adverse events in the SGLT2i group was mostly comparable with those in the non-SGLT2i group except for diseases of the liver, pain, hypertensive diseases, and metabolic disorders, which showed significantly higher odds in the SGLT2i group. Conclusions SGLT2i add-on treatment is an effective and safe therapeutic option for patients with T2DM in the real-world practice setting. Supplementary Information The online version contains supplementary material available at 10.1007/s13300-023-01518-x.

show abstract

Section: Introductionmentioning

confidence: 99%